Frustrated, get in line, there are 10-Year+ shareholders on this board, do not focus on the past, like the financing or not, it is behind us now, we have money, multiple Phase II trials, greater media coverage/communications and favorable BioTech market dynamics. It is all about execution. Glynn Wilson needs to execute here and now. If Glynn can not deliver the goods in a short period of time, we have the money to move Kenney or another high potential candidate into the CEO role and let Glynn assume a lesser role like Chairman or advisor. Now is the time to monetize the full value for TPIV, we need the right person in place to accomplish this now, Glynn is the guy for now but he needs to be on a short leash and the shareholders need to be prepared to make appropriate changes if necessary.
News 
Market Data 
Discover 
